REPL News and Press, Replimune Group Inc. From 07/22/25

A look at the top 10 most actives in the United States Opendoor Technologies Inc (OPEN) rose 6.9% to $3.431 on volume of 239,838,844 shares Dragonfly Energy Holdings Corp (DFLI) rose 122.3% to $0.5925 on volume of 229,549,696 shares Wang & Lee Group Inc. (WLGS) rose 27.0% to $0.0658 on ...

Philadelphia, Pennsylvania--(Newsfile Corp. - July 22, 2025) - Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Replimune Group, Inc. ("Replimune") (NASDAQ: REPL). On July 22, 2025, Replimune announced that the FDA ". . . issued a Complete Response...

2025-07-22 07:34:57 ET More on Replimune Group Replimune Group, Inc. (REPL) Q4 2025 Earnings Call Transcript Replimune Group: Analysts Are More Optimistic Than The Market Replimune: Scope Goes Beyond That Of RP1 Oncolytic Targeting For Melanoma Replimune Grou...

WOBURN, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter ...

2025-07-18 12:02:14 ET Investment Overview When I last covered Iovance Biotherapeutics, Inc. ( IOVA ) in a note for Seeking Alpha back in early April, I gave the San Carlos, California based biotech's stock a Sell rating, with shares priced at $3.25. That has proven to b...

2025-07-02 09:35:55 ET ... Read the full article on Seeking Alpha For further details see: Iovance Biotherapeutics: ASCO Update, Competitor Data And The Road Ahead

2025-06-17 21:14:09 ET This article is part of a series that provides an ongoing analysis of the changes made to Baker Brothers' 13F stock portfolio on a quarterly basis. It is based on Baker Brothers' regulatory 13F Form filed on 05/15/2025. The 13F portfolio value decreased from $...

2025-06-12 08:36:26 ET Investment Thesis Read the full article on Seeking Alpha For further details see: Delcath Systems: Growing Fast, But Business Model Is Fragile

WOBURN, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to newly hired non-executive employees. The Compan...

- RP1 plus nivolumab generated robust responses in both injected and non-injected lesions - - Deep/visceral injections, including into the liver and lung, resulted in numerically higher rates of response compared to superficial injections only and were generally well tolerated - WOB...